View Older Stories View More Recent Stories
-
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
-
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline
-
Form SC 13G/A NewAmsterdam Pharma Co Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Latest Updates of 7 Viva's Portfolio Companies
-
UroGen Pharma (URGN) Announces $120 Million Private Placement of Ordinary Shares
-
UroGen Announces $120 Million Private Placement of Ordinary Shares
-
Form SC 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
-
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
-
DTx Pharma announces acquisition by Novartis
-
Aerovate Therapeutics (AVTE) Appoints Habib Dable To Its Board
-
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
-
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Biotech firms target weight-loss drugs without Wegovy's side-effects
-
Form SC 13G Talaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Orchard Therapeutics (ORTX) Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
-
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
-
Aeglea BioTherapeutics (AGLE) Acquires Spyre Therapeutics
-
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
-
Talaris Therapeutics (TALS) and Tourmaline Bio Announce Merger Agreement
-
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
-
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs
-
Form SC 13D/A DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer
-
Form SC 13D/A Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)
-
Form SC 13G 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
-
T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting
-
Jnana Therapeutics to Present at the Jefferies Healthcare Conference
-
Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU
-
Form SC 13D/A Icosavax, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline
-
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
-
Be Biopharma to Present at the Jefferies Healthcare Conference
-
MBX Biosciences to Participate in Jefferies Healthcare Conference
